Distinct genital tract HIV-specific antibody profiles associated with tenofovir gel.

Abstract

Correction to: Mucosal Immunology (2016); advance online publication, 27 January 2016; doi: 10.1038/mi.2015.145 The version of this article published online contained several incorrect elements: some of the authors' names and some of the affiliations; Figures 1 and 3; Tables 2 and 3; some references; Supplementary Figures 2–6. Correction to: Mucosal Immunology (2016); advance online publication, 27 January 2016; doi: 10.1038/mi.2015.145 The version of this article published online contained several incorrect elements: some of the authors' names and some of the affiliations; Figures 1 and 3; Tables 2 and 3; some references; Supplementary Figures 2–6. Correction to:Mucosal Immunology (2016); advance online publication, 27 January 2016; doi: https://doi.org/10.1038/mi.2015.145 The version of this article published online contained several incorrect elements: some of the authors' names and some of the affiliations; Figures 1 and 3; Tables 2 and 3; some references; Supplementary Figures 2–6. The Supplementary Figures appear online via the online version of this erratum. The article published in this issue incorporates all the corrected elements listed above. The publisher regrets the errors. Distinct genital tract HIV-specific antibody profiles associated with tenofovir gelMucosal ImmunologyVol. 9Issue 3PreviewThe impact of topical antiretrovirals for pre-exposure prophylaxis on humoral responses following HIV infection is unknown. Using a binding antibody multiplex assay, we investigated HIV-specific IgG and IgA responses to envelope glycoproteins, p24 Gag and p66, in the genital tract (GT) and plasma following HIV acquisition in women assigned to tenofovir gel (n=24) and placebo gel (n=24) in the CAPRISA 004 microbicide trial to assess if this topical antiretroviral had an impact on mucosal and systemic antibody responses. Full-Text PDF Open Archive